Moving Beyond a Buzzword: How small- to mid-sized biotechs can adopt patient centricity in oncology trials
Guest Commentary: Even small steps toward patient engagement can improve cancer trial recruitment, reduce costs
A major benefit of integrating the patient voice into clinical trials is the ability to speed enrollment, yet few companies take advantage of this due to the perception that it is too costly and time-consuming. We maintain that a tailored, step-wise approach to patient centricity can make it feasible even for small companies.
Despite the fact that 70% of Americans have reported being inclined or even very willing to participate in a trial, only about 5% of adult cancer patients are enrolled in clinical trials, according to an FDA report released in May. While eligibility criteria exclude some of these patients, many more could participate. Adopting patient-centric elements into oncology clinical trials has the potential to significantly impact recruitment and retention.
There are multiple opportunities for companies to integrate the patient perspective, either on their own or with the help of CROs. While the task can seem daunting for small- or medium-sized biotechs with limited financial or human resources, it doesn’t have to be -- even making one change at a time can pay off.
Now is the time to adopt patient-centric strategies that not only focus on patient needs, but also maintain cost efficiency. Some of these